ArticleEuropean journal of nuclear medicine and molecular imaging2021
Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity - initial experience and comparison to [
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?Contrast media & molecular imaging · 2022Pooled it
- Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [International journal of molecular sciences · 2021Pooled it
- Spatial Proximity of Cancer-Associated Fibroblasts to Tumor and Osteoclasts Suggests a Coordinating Role in OSCC-Induced Bone Invasion: A Preliminary Study.Biomedicines · 2025Article
- Fibroblast activation protein-α is a potential prognostic biomarker related to ferroptosis in head and neck squamous cell carcinoma.Biochemistry and biophysics reports · 2025Article
- Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Review
- Role ofCancers · 2024Review
- From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment.Cellular oncology (Dordrecht, Netherlands) · 2024Review
- Evaluating the Patterns of FAPI Uptake in the Shoulder Joint: a Preliminary Study Comparing with FDG Uptake in Oncological Studies.Molecular imaging and biology · 2024Article
- Recent topics in fibroblast activation protein inhibitor-PET/CT: clinical and pharmacological aspects.Annals of nuclear medicine · 2024Review
- The Role and Application of Fibroblast Activating Protein.Current molecular medicine · 2024Review
- Nano-drug delivery system targeting FAP for the combined treatment of oral leukoplakia.Drug delivery and translational research · 2024Article
- The comparative utility of FAPI-based PET radiotracers over [American journal of nuclear medicine and molecular imaging · 2024Review
- Diagnostic Accuracy of [Pharmaceuticals (Basel, Switzerland) · 2023Review
- Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature.Life (Basel, Switzerland) · 2023Review
- Molecular imaging of arterial fibroblast activation protein: association with calcified plaque burden and cardiovascular risk factors.European journal of nuclear medicine and molecular imaging · 2023Article
- The performance ofEuropean journal of nuclear medicine and molecular imaging · 2023Article
- Development of a fibroblast activation protein-targeted PET/NIR dual-modality probe and its application in head and neck cancer.Frontiers in bioengineering and biotechnology · 2023Article
- Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma.Journal of translational medicine · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWhile [
methodsTen consecutive, treatment-naïve patients (8 males, 2 females; mean age, 62 ± 9 years) with biopsy-proven OSCC underwent both whole-body [
results[
conclusionFAP-directed PET/CT in OSCC seems feasible. Future research to investigate its potential to improve patient staging is highly warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.